Records containing: Relapsing-Remitting Multiple Sclerosis
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-03-30A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light Levels (SOSTOS)
-
CLINICAL_TRIALS study record update · 2026-02-19Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2026-02-17Assessment of Attentional and Executive Disorders in Multiple Sclerosis Using Techniques of Virtual Reality
-
CLINICAL_TRIALS study record update · 2026-01-30A Phase III Multicenter, Randomized, Double-blind, Double-dummy Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2025-07-20Open-Label, Randomized, Multicenter, Multiple-Dose,Active-Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2025-03-05PET with [18F]Flumazenil As an Index of Neurodegeneration in MS: Sensitivity At an Early Disease Stage and Pathophysiological Meaning
-
CLINICAL_TRIALS study record update · 2024-12-18Cladribine Tablets in Highly-active Relapsing Multiple Sclerosis - Real-World Effectiveness in UK Clinical Practice (CAMELOT-MS)
-
CLINICAL_TRIALS study record update · 2024-08-23Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt
-
CLINICAL_TRIALS study record update · 2024-06-03Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Patients
-
CLINICAL_TRIALS study record update · 2024-04-08TOP: TYSABRI Observational Program
-
CLINICAL_TRIALS study record update · 2023-03-24Behavior and Activity Monitoring in Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2022-03-16A Randomised Controlled Trial to Compare Ocrelizumab or Alemtuzumab With Autologous Hematopoietic Stem Cell Transplantation (aHSCT) in High Inflammatory Multiple Sclerosis (COAST)
-
CLINICAL_TRIALS study record update · 2021-07-29Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod: a Monocentric, Prospective, One Year, Baseline-to-treatment, Open-label Single Group Pilot Trial
-
CLINICAL_TRIALS study record update · 2021-04-08A Randomised Controlled Pilot Study to Compare the Effects of Prolonged Fasting and Ketogenic Low Glycemic Load Treatment on Health Related Quality of Life in Relapsing-remitting Multiple Sclerosis.
-
CLINICAL_TRIALS study record update · 2020-12-31A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2020-03-19A Multicenter, Open-Label Study Evaluating the Effectiveness of Oral Tecfidera™ (Dimethyl Fumarate) on MS Disease Activity and Patient-Reported Outcomes in Subjects With Relapsing-Remitting Multiple Sclerosis in the Real-World Setting
-
CLINICAL_TRIALS study record update · 2020-01-21Treatment of Autologous Mesenchymal Stem Cells Derived From Bone Marrow as a Potential Therapeutic Strategy for the Treatment of Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2019-12-04A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301
-
CLINICAL_TRIALS study record update · 2019-07-18Open Label Study to Evaluate the Safety of Copaxone® and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone
-
CLINICAL_TRIALS study record update · 2019-07-11Assessment of the Effectiveness of Guided by a Physiotherapist Versus Non-guided Pelvic Floor Exercises for Urinary Incontinence (UI) in Patients With Relapsing-Remitting (RR) Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2019-02-20Mitochondrial Dysfunction and Disease Progression
-
CLINICAL_TRIALS study record update · 2019-02-12A Multicenter, Observational, Open-Label, Single-Arm Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
-
CLINICAL_TRIALS study record update · 2019-01-04MRI and Clinical Disease Activity in Patients Treated Long Term With Natalizumab
-
CLINICAL_TRIALS study record update · 2018-11-20A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of BG00012 in Subjects From the Asia-Pacific Region and Other Countries With Relapsing-Remitting Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2018-11-15Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis